Search

Displaying results 3071 - 3080 of 10000 in total
  1. Drug

    Elismetrep

    go.drugbank.com/drugs/DB15287
    Investigational

    Elismetrep is under investigation in clinical trial NCT02429102 (A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy Subjects).

  2. Drug

    MK-1496

    go.drugbank.com/drugs/DB12763
    Investigational

    MK-1496 has been used in trials studying the treatment of Neoplasms and Malignant.

  3. Drug

    MK-5108

    go.drugbank.com/drugs/DB12556
    Investigational

    MK-5108 has been used in trials studying the treatment of Cancer, Neoplasms, Tumors.

  4. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    By binding to both targets simultaneously, linvoseltamab redirects T cells toward myeloma cells, forming an immunological synapse that activates T-cell–mediated cytotoxicity. … marketed as Lynozyfic™, is a bispecific human IgG4 monoclonal antibody developed by Regeneron that promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T

    Categories: Bispecific B Cell Maturation Antigen-directed CD3 T Cell Engager
  5. Drug

    Rindopepimut

    go.drugbank.com/drugs/DB05374
    Investigational

    The US FDA granted it Breakthrough Therapy Designation for glioblastoma in Feb 2015. … Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases.

  6. Drug

    Zorecimeran

    go.drugbank.com/drugs/DB15843
    Investigational

    The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. … As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence Phase 1 clinical trials of this vaccine (NCT04449276).

  7. Drug

    AMG-119

    go.drugbank.com/drugs/DB17363
    Investigational

    AMG-119 are CAR-T cells targeting delta-like ligand 3 (DLL3).[A254811]

  8. Drug

    MK-7622

    go.drugbank.com/drugs/DB12897
    Investigational

    MK-7622 has been used in trials studying the treatment of Alzheimer's Disease.

  9. Drug

    Maftivimab

    go.drugbank.com/drugs/DB15899
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … Ebola virus (EBOV) remains an important human pathogen within the _Ebolavirus_ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%.

  10. Drug

    Respiratory syncytial virus vaccine, adjuvanted

    go.drugbank.com/drugs/DB17762
    ApprovedInvestigational

    It comprises lyophilized recombinant respiratory syncytial virus glycoprotein F (RSVPreF3) stabilized in pre-fusion conformation as the antigen component, which is reconstituted at the time of use with … [L46352] It was also later approved by Health Canada on August 4, 2023,[L47666] and the EMA in March 2025.[L52380]